Omini (Future 40 2019) raises 1,7M€ to develop a new portable blood testing technology

Part of Entrepreneur First and Founders Program, Omini is a French MedTech company developing a new generation of blood tests for personalized healthcare.

Future 40 companies continue to raise! After Axel, Stonly and Kinetix, Omini just announced a first seed round of 1.7M€. Created by Joanne Kanaan and Anna Shirinskaya in 2019, Omini brings clinical chemistry into a new medical era. Their company, who was selected in Future 40 2019, develops portable biosensing devices for immediate blood tests at the patient bedside, using a patented biosensor technology that brings together fast and accurate biomarkers measurements in a connected and easy to use device.


Omini raised its first round with deeptech investor Entrepreneur First and renowned French Business Angel networks (BADGE, AMBA, Angel Santé, ISEAD BA, WeLike and PSBA), strategic angels and Bpifrance. This fundraising will help the company to accelerate industrialization of its product.

“We are very pleased with the success of this seed round which brought together investors passionate about innovation. Faced with strong competition in the field of portable blood testing, Omini will be the first to offer instantaneous and accurate multi testing devices that are portable, easy to use, minimally invasive and affordable. We will enable testing and measurement outside healthcare facilities and enhance patient monitoring, to improve medical coverage and reduce associated medical expenses”, said Joanne Kanaan.